The objectives of the SATE team are to describe the molecular mechanisms and reprogramming pathways that, in response to various types of cellular stress, participate in the organization of epithelial tumors as a pseudo-organ; to understand the signals involved in the escape from tumor suppression; and to identify therapeutic approaches to reactivate this suppression.
We focus our research, albeit non-exclusively, on breast carcinoma. We concentrate on the effects of stress on mitochondrial integrity and cell survival (mitochondrial apoptosis pathway in particular) and on the mechanisms of resolution of these stresses during the progression and treatment of these epithelial cancers.
Our positioning at the interface of upstream research and transfer research allows us, by taking full advantage of the complementary expertise of the researchers, clinicians and veterinarians who constitute our team, to study samples derived from patients in addition to relevant models of cancer pathology.
We are organized into four interconnected working groups, exploring:
1 The biochemical and cellular determinants of mitochondrial priming/processing in individual cells and in populations (L. Maillet, S. Barillé-Nion, M. Le Breton)
2 The role of mitochondrial stress and cell death on the organization of epithelial diversity and the influence of primary ciliogenesis in cancer stem cell resistance (F. Gautier, V. Guen)
3 Reciprocal influences between heterotypic intercellular communications in the microenvironment, mitochondrial signaling and cell survival (F. Souazé)
4 Epigenetic events related to mitochondrial signaling and cell survival in tumor ecosystems (P-F. Cartron, L.Lalier)
Our common objectives are to:
– to identify novel mechanisms regulating cell death/survival balance in malignant cell populations
– characterize what determines, and what is determined, by mitochondrial stress in tumor ecosystems
-Define cellular targets, the therapeutic window of agents targeting cell survival mechanisms, and longitudinal markers of response to these agents
To reach them, we take advantage of clinically relevant models, including organotypic cultures, organoids and xenografts derived from patients (PDX). We use single cell analysis of breast tumors and work closely with bioinformaticians for the analytical part. The team members actively participate in many networks such as SIRIC ILIAD, CGO (co-head of the CasTHor and NET networks, CNRS GDR Micronit) to expand our know-how and share our expertise with the scientific community.
One of the strengths of our team is that it brings together scientists with very diverse backgrounds going from cell biology to molecular biology with a clear attraction for innovation and new technologies.
If, like us, you are interested in understanding cancers and imagining tomorrow’s personalized medicine in oncology, do not hesitate to contact us.
Philippe Juin, DR INSERM
Sophie Barillé-Nion, CR INSERM
Laurent Maillet, CR INSERM
Frédérique Souazé, CR INSERM
Pierre-François Cartron, CR INSERM
Vincent Guen, CR INSERM
Fabien Gautier, CR ICO
Magali Le Breton, MCU
Lisenn Lalier, CR ICO
Floriane Briand, AI
Aurélie Fétiveau, TR
Julie Roul, TR
Arulraj Nadaradjane, TR
Gwenola Cartron, AI
Marie-Pierre Joalland, TR
Adrien Breton, TR
Mario Campone, PU-PH ICO
Pascal Jézéquel, PH ICO
Jean-Sébastien Frénel, PH ICO
Olivier Kerdraon, PH ICO
Judith Raimbourg, PH ICO
Marie Robert, PH ICO
Frédérique Nguyen, MC ONIRIS
Lisa Nocquet, PhD Student
Nina-Maya Belaid, PhD Student
Florestan Courant, PhD Student
Orlane Bosson, PhD Student
Alison Dumont, PhD Student
Florian Chocteau, PhD Student